Hematide entered into phase 3 clinical program to treat anemia in chronic renal failure patients in Japan
22-Feb-2010 -
Takeda Pharmaceutical Company Limited announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase 3 clinical program in Japan.
Hematide™, a synthetic, ...
anemia
chronic renal failure
dosing
+5